DOUG RICE
DOUG RICE's purchase track record
DOUG RICE has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/21/2023 | MDXG | $36K | +11.5% | +10.3% | +17.3% |
| 11/19/2021 | OFIX | $42K | +1.2% | -13.7% | -17.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| MDXG | ▼ Sell | Tax Withholding | 12,749 | $50K | 7/2/2026 | View on chart |
| MDXG | ▲ Buy | Option Exercise | 243,000 | $1.1M | 3/10/2026 | View on chart |
| MDXG | ▼ Sell | Tax Withholding | 96,363 | $434K | 3/10/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 74,163 | $0 | 3/4/2026 | View on chart |
| MDXG | ▼ Sell | Tax Withholding | 12,749 | $81K | 7/3/2025 | View on chart |
| MDXG | ▲ Buy | Grant | 45,929 | $0 | 3/3/2025 | View on chart |
| MDXG | ▼ Sell | Tax Withholding | 12,749 | $87K | 7/8/2024 | View on chart |
| MDXG | ▲ Buy | Grant | 58,478 | $0 | 3/1/2024 | View on chart |
| MDXG | ▲ Buy | Open Market | 5,000 | $36K | 11/21/2023 | View on chart |
| MDXG | ▲ Buy | Grant | 97,200 | $0 | 7/5/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,937 | $0 | 4/11/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 363 | $12K | 4/2/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 867 | $29K | 4/1/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 1,317 | $44K | 4/1/2022 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 385 | $13K | 4/1/2022 | View on chart |
| OFIX | ▲ Buy | Grant | 22,131 | $0 | 2/1/2022 | View on chart |
| OFIX | ▲ Buy | Open Market | 1,400 | $42K | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.